MarginsXMarginsX
Home › Markets › Health Care › CMND

Clearmind Medicine Inc. Common Shares (CMND)

CMND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.18
-7.67% on the day
Market cap
$2.1M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCMND on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001892500
SEC industry codePharmaceutical Preparations
Incorporated inCanada

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
9.9 months
$3.9M cash at October 31, 2025
Share count, 1 year
See the dilution note
+14273.0% over 3 years
Going-concern doubt
Yes
20-F filed January 20, 2026
Insider net buying, 12 months
-$91K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt on the Company's ability to continue as a going concern."
20-F 2026-01-20
Cash and burn$3.9M cash; operating cash flow -$1.2M a quarter.Report 2025-10-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-01-19
Reverse splits, 3 years4; latest 1-for-8 on 2026-10-05Source 2026-10-05
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2025-12-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBrightman Almagor Zohar & Co., Tel Aviv, IsraelPCAOB Form AP 2026-02-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $91K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-10-31
Not filed-$3.9M-$4.7M$3.9MNo debt tagsNeeds four quarters20-F 2026-01-20
FY 2024
2024-10-31
Not filed-$5.3M-$4.9M$6.6MNo debt tagsNeeds four quarters20-F 2026-01-20
FY 2023
2023-10-31
Not filed-$8.6M-$6.3M$5.4MNo debt tagsNeeds four quarters20-F 2026-01-20
FY 2022
2022-10-31
Not filed-$6.9M-$3.7M$129KNo debt tagsNeeds four quarters20-F 2025-01-22
FY 2021
2021-10-31
Not filed-$2.7M-$2.1M$3.4MNo debt tagsNeeds four quarters20-F/A 2024-03-18

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1
POS AM2026-06-15
Latest annual report
ANNUAL REPORT
20-F2026-01-20
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-16

Source: SEC EDGAR submissions feed, 375 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-18.9%
1 month-27.3%
3 months-69.4%
Year to date-96.9%
1 year-99.6%
From 52-week high-99.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M
DCOYDecoy Therapeutics Inc.$0.9010-7.61%$2.1M
JUNSJupiter Neurosciences Inc.$1.70-8.11%$2.2M
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
ONCOOnconetix Inc.$2.91-9.35%$1.9M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
HCWBHCW Biologics Inc.$0.8000+3.48%$1.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier